Citadel Advisors’s Trillium Therapeutics Inc. TRIL Stock Holding History

Citadel Advisors’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-80,100	Closed	-$1.41M	–	15483
2021 Q3	$1.41M	Sell	80,100 -33,600	-30%	-$393K	﹤0.01%	7259
2021 Q2	$1.1M	Sell	113,700 -33,300	-23%	-$313K	﹤0.01%	8113
2021 Q1	$1.58M	Sell	147,000 -36,600	-20%	-$453K	﹤0.01%	6978
2020 Q4	$2.7M	Buy	183,600 +68,100	+59%	+$982K	﹤0.01%	4755
2020 Q3	$1.64M	Sell	115,500 -123,400	-52%	-$1.23M	﹤0.01%	5095
2020 Q2	$1.93M	Buy	238,900 +142,600	+148%	+$882K	﹤0.01%	4643
2020 Q1	$389K	Buy	+96,300	New	+$364K	﹤0.01%	6874

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Citadel Advisors's TRIL Position: Q4 2021 in Review

Citadel Advisors sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 798,500 shares — an estimated $14M sold.

Citadel Advisors first reported a position in TRIL in Q4 2017 and held it in 10 quarters. The position peaked at $60.4M in Q4 2020. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Citadel Advisors reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Citadel Advisors sold 798,500 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $14M.
Citadel Advisors first reported a position in Trillium Therapeutics Inc. in Q4 2017 and held it in 10 quarters.
Citadel Advisors's Trillium Therapeutics Inc. position peaked at $60.4M in Q4 2020.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Citadel Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.